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Tre'atment of vaginal candidiasis in
pregnancy with a single clotrimazole
500 mg vaginal pessary
B. G. L1NDEQUE, W. A. VAN NIEKERK
Patients and methods
Results
TABLE I. CANDIDA SPECIES ISOLATED
No. of
patients
Ofthe 46 patients included in the study, 4 were lost to follow-up,
mostly owing to delivery. The data on the remaining 42 patients
were used in the analysis. The most commonly encountered
symptom was vaginal discharge, occurring in 65% ofthe patients.
Pruritus and a burningsensation were other frequent complaints.
In only 17% of patients was the diagnosis of vulvitis made. The
Candida species isolated are listed in Table I.
44
1
1
46
Primary infection
C. albIcans
C. troplcall,
C. parapsllos/,
Forty-six patients in the second and third trimesters ofpregnancy
who had clinical and microscopic evidence ofvaginal candidiasis
were included in the study. High vaginal swabs were taken and
positive cultures for Candida were obtained in each case before
commencement of treatment. The culture medium used was
Sabouraud agar.
Patients in the first trimester ofpregnancy wert: excluded from
the study in order to exclude the possibility of possible
teratogenic effects of the drug. Other criteria for exclusion were
concurrent trichomoniasis and the use of local or oral antifungal
therapy in the preceding 4 weeks.
After positive cultures for Candida had been obtained the
pessary containing clotrimazole 500 mg was inserted into the
vagina by one of the investigators. Patients were advised to
abstain from intercourse for 1 week after treatment in order to
avoid reinfection. Patients' sexual partners were requested to
treat the glans penis with topical clotrimazole cream during this
period.
Examinations were repeated 1 week and 1 month after
treatment. Clinical and microscopic examinations were per-
formed at each visit, and high vaginal swabs were taken for
culture. Patients were requested to notify the investigators if
local irritation or other untoward effects occurred.
Patients with primary vaginal candidiasis, recurrent infection
and other concomitant disease, e.g. diabetes mellitus, were all
included in the study group.
S Atr Med J 1984; 65: 123-124.
Summary
A single vaginal pessary containing clotrimazole 500
mg (Canesten; Bayer-Miles) was used to treat candi-
diasis during a prospective, mycologically controlled
trial among 46 patients in the second and third
trimesters of pregnancy. Positive cultures were
obtained from vaginal swabs before commencement
of treatment Swabs were taken 1 week and 1 month
after treatment Four patients were lost to follow-up.
One week after treabnent 83,3% of the patients were
cured on microscopic and mycological examination,
and all of the patients had relief of symptoms. The
recurrence rate was 5,7% after. 1 month. Of the 7
patients in whom treatment was unsuccessful, 3 were
available for repeat treatment and ·all 3 responded
successfully to a second course.
Vaginal candidiasis is one of the most commonly encountered
infections among obstetric patients. The incidence of vaginal
candidiasis in pregnancy is higher than that among non-
pregnant women. 1,2 The hormonal milieu of pregnancy, with a
fall in vaginal pH and increased vaginal epithelial cell oestrogen
and glycogen contents, favours fungal growth.3 The impaired
cellular immunity" and decreased candidacidal effects of leuco-
cytes associated with pregnancyS may also contribute to the
increased incidence. Other predisposing factors include obesity,
diabetes mellitus, iron deficiency anaemia, immunosuppressive
therapy and the prolonged use ofbroad-specrrum antibiotics.6
Several forms of therapy have been developed and are in
current use. However, candidiasis is known often to be chronic
or recurrent.! Furthermore, Masterton er al.7 noted that 4% of
patients with vaginal candidiasis given a 14-day course of local
therapy did not even start using their medication, and that
approximately 50% ofthese patients discontinued therapy before
completion of the full course. The ideal method of therapy
should be effective with a low risk of recurrence of vaginitis and
associated with good patient acceptance and compliance.
For the first time a single vaginal pessary containing clotri-
mazole 500 mg (Canesten; Bayer-Miles) was used as complete
therapy for vaginal candidiasis in pregnancy in an open,
prospective, mycologically controlled study. The. aim of the
study wastQ assess by clinical and mycological criteria the cure
rate for vaginal candidiasis using this treatment.
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Second positive culture
C. albIcans
C. parapsllos/s
C. gu""ermondl
4
2
1
7
TABLE Ill. REPORTED CURE RATES WITH
CLOTRIMAZOLE IN PREGNANT PATIENTS
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One week after treatment 35 patients (83,3%) were cured on
microscopic and mycological examination. All patients expe-
rienced relief of symptoms. Of the 7 patients (16,7%) who failed
to respond, 3 were available for repeat treatment and all 3
responded to a second course. In 2 of these patients the causative
organism found after a second culture was a Candida species
different from the original one, indicating that re-infection had
taken place.
One month after treatment 2 of the patients who had originally
been treated successfully again had positive cultures for C.
albicans. The recurrence rate was therefore 5,7%. No patient
experienced any adverse effects of treatment.
100 mg/d for 6 days, intravaginally
Frerich and Gad (1977)21
Haram and Digranes (1978)'9
500 mg, single dose intravaginally
Present study
% cure
83
82
83,3
Discussion
TABLE 11. REPORTED CURE RATES WITH CLOTRIMAZOLE
IN NON-PREGNANT PATIENTS
Vaginal candidiasis in pregnancy is often recurrent or chronic,
probably because of the continuation of hormonal changes. The
patient experiences severe irritation and pruritus, even to the
extent of developing the psychological problems of chronic
illness.6
The importance ofvaginal candidiasis in pregnancy, however,
is the fact that the fetus can also be affected, either transplacen-
tally, a rare occurrence which is usually fatal, or in the vagina at
birth. 2 Ascending infection from the birth canal spreading to the
fetus and amniotic fluid is also possible but not yet proved. 2,B
The most common Candida infection of neonates is oral
thrush, but extensive infection - dermatitis and disseminated
neonatal candidiasis - may occur. 2,9 Sixty-six per cent ofbabies
born to mothers with vaginal candidiasis have ~ositive cultures
for Candida from the oral cavity after birth, ,10,11 but not all
develop clinical thrush. Approximately 5% of all newborns are
estimated to develop thrush. 2 Some predisposing factors include
prematurity, intra-uterine growth retardation, certain resusci-
tation procedures and especially a poor immunological response
against Candida.2 Protection against thrush is offered by colo-
sual cells in breast milk, which have been found to have greater
phagocytic effects on Candida than leucocytes have. 12
The aim of therapy for vaginal candidiasis is eradication of the
organism, which would cure the patient and protect the baby.
Clotrimazole is a synthetic imidazole derivative which acts by
changing fungal membrane permeability and thus causing loss of
essential substances from the fungal cell. Fungal protein synthesis
is also inhibited. n,14 After vaginal application of clotrimazole
pessaries epithelial penetration takes place, but no systemic
absorption of the drug has been found. The drug has been used
in pregnant patients without any reported ill-effects on the
fetus. IS
The efficacy of clotrimazole has been proved in several
reported studies (Table ll). 7,16-20 In pregnant patients cure rates
comparable to the results of the present study have been reported
(Table Ill). 19,21
100 mg/d for 6 days, intravaginally
Lohmeier (1974)'6
Widholm (1974)17
Masterton et al. (1975)'8
Haram and Digranes (1978)19
Robertson (1978)20
100 mg 2x/d for 3 days, intravaginally
Masterton et al. (1976)7
% cure
71
81
93
89
75
89
The reported incidence of recurrence varies from 4,2% te 24%
with 6-day courses of therapy.2,22 In the current study a
recurrence rate ofonly 5,7% was found. 0 resistance ofCandida
to any imidazole derivative has been reported, I and all investi-
gators have recorded good patient acceptance and a very low
incidence of side-effects.
Conclusion
The results of this study compare very favourably with other
reported results, indicating that treatment of vaginal candidiasis
in pregnant patients with a single clouimazole 500 mg vaginal
pessary is effective and associated with a low rate of recurrence.
Specific advantages of the single-dose therapy include: (i)
proven effectiveness; (ii) absence of adverse effects; (iii) rapid
relief of symptoms for all patients; (iv) very good patient
acceptance and compliance; (v) no increased risk of recurrence;
and (VZ) simplicity.
We thank the Medical Superintendent of Tygerberg Hospital for
permission to publish.
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